NASDAQ:URGN - Nasdaq - IL0011407140 - Common Stock - Currency: USD
4.05
+0.12 (+3.05%)
The current stock price of URGN is 4.05 USD. In the past month the price decreased by -62.36%. In the past year, price decreased by -69.55%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.83 | 323.41B | ||
AMGN | AMGEN INC | 13.41 | 149.70B | ||
GILD | GILEAD SCIENCES INC | 14.01 | 134.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.30B | ||
REGN | REGENERON PHARMACEUTICALS | 13.36 | 63.90B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.23B | ||
ARGX | ARGENX SE - ADR | 98.17 | 35.18B | ||
ONC | BEIGENE LTD-ADR | 6.16 | 25.99B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.45B | ||
NTRA | NATERA INC | N/A | 22.01B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.34B | ||
BIIB | BIOGEN INC | 8.06 | 18.69B |
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
UROGEN PHARMA LTD
9 Ha'ta'asiya St
Ra'anana 08540 IL
CEO: Elizabeth Barrett
Employees: 235
Phone: 97297707601
The current stock price of URGN is 4.05 USD. The price increased by 3.05% in the last trading session.
The exchange symbol of UROGEN PHARMA LTD is URGN and it is listed on the Nasdaq exchange.
URGN stock is listed on the Nasdaq exchange.
14 analysts have analysed URGN and the average price target is 33.28 USD. This implies a price increase of 721.67% is expected in the next year compared to the current price of 4.05. Check the UROGEN PHARMA LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
UROGEN PHARMA LTD (URGN) has a market capitalization of 186.75M USD. This makes URGN a Micro Cap stock.
UROGEN PHARMA LTD (URGN) currently has 235 employees.
The Revenue of UROGEN PHARMA LTD (URGN) is expected to grow by 31.54% in the next year. Check the estimates tab for more information on the URGN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
URGN does not pay a dividend.
UROGEN PHARMA LTD (URGN) will report earnings on 2025-08-11, before the market open.
UROGEN PHARMA LTD (URGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.18).
The outstanding short interest for UROGEN PHARMA LTD (URGN) is 12.03% of its float. Check the ownership tab for more information on the URGN short interest.
ChartMill assigns a fundamental rating of 3 / 10 to URGN. URGN may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months URGN reported a non-GAAP Earnings per Share(EPS) of -3.18. The EPS increased by 6.47% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -55.91% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 84% to URGN. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 6.8% and a revenue growth 31.54% for URGN